产品
编 号：F744101
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1326232-46-5
产品详情
生物活性：
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.
体外研究：
Anifrolumab (67.7?nM; 20 min) induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation.Anifrolumab (1 and 10 μg/mL; 6 or 7 d) suppresses differentiation of B cells into plasma cells.Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3?nM for the IFN-α subtypes, and 0.03?nM and 0.07?nM for IFN-β and IFN-ω, respectively.Anifrolumab (67.7?nM) dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production.
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.
体外研究：
Anifrolumab (67.7?nM; 20 min) induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation.Anifrolumab (1 and 10 μg/mL; 6 or 7 d) suppresses differentiation of B cells into plasma cells.Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3?nM for the IFN-α subtypes, and 0.03?nM and 0.07?nM for IFN-β and IFN-ω, respectively.Anifrolumab (67.7?nM) dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备